Risk of Infection With Ustekinumab and Tofacitinib vs TNF-α Antagonists in IBD Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Clinical Gastroenterology and Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Risk of infections with ustekinumab and tofacitinib compared to tumor necrosis factor α antagonists in inflammatory bowel diseases
Clin. Gastroenterol. Hepatol. 2022 Jan 20;[EPub Ahead of Print], D Cheng, B Kochar, T Cai, AN AnanthakrishnanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.